The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis

Annals of the New York Academy of Sciences

Volumn 1281, Issue 1, 2013, Pages 16-35

  Padgett, Lindsey E ^a   Broniowska, Katarzyna A ^b   Hansen, Polly A ^b   Corbett, John A ^b   Tse, Hubert M ^a  

^a University of Alabama at Birmingham   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cytokines; Reactive oxygen species; Type 1 diabetes

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; INTERLEUKIN 1; INTERLEUKIN 12; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SUPEROXIDE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; AEROBIC METABOLISM; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA DAMAGE; GENE SILENCING; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRACELLULAR SIGNALING; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MITOCHONDRIAL RESPIRATION; NONHUMAN; NONOBESE DIABETIC MOUSE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; SECOND MESSENGER; T LYMPHOCYTE ACTIVATION; UNFOLDED PROTEIN RESPONSE;

EID: 84875674753     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06826.x     Document Type: Article

References (195)

1. van Belle, T.L., K.T. Coppieters & M.G. von Herrath. 2011. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91: 79-118.
2. Haskins, K. et al. 2003. Oxidative stress in type 1 diabetes. Ann. N.Y. Acad. Sci. 1005: 43-54.
3. Curtsinger, J.M. et al. 1999. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162: 3256-3262.
4. Pape, K.A. et al. 1997. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 159: 591-598.
5. Tse, H.M., M.J. Milton & J.D. Piganelli. 2004. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic. Biol. Med. 36: 233-247.
6. Patterson, C.C. et al. 2012. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55: 2142-2147.
7. Patterson, C.C. et al. 2009. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373: 2027-2033.
8. Redondo, M.J. et al. 2008. Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med. 359: 2849-2850.
9. Banting, F.G. & C.H. Best. 1922. The internal secretion of the pancreas. J. Lab. Clin. Med. 7: 465-480.
10. Willcox, A. et al. 2009. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155: 173-181.
11. Herold, K.C. et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
12. Bougneres, P.F. et al. 1988. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 318: 663-670.
13. Keymeulen, B. et al. 2010. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53: 614-623.
14. Voltarelli, J.C. et al. 2007. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576.
15. Huurman, V.A. et al. 2008. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 3: e2435.
16. Katz, J., C. Benoist & D. Mathis. 1993. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur. J. Immunol. 23: 3358-3360.
17. Serreze, D.V. et al. 1994. Major histocompatibility complex class I-deficient NOD-B2m null mice are diabetes and insulitis resistant. Diabetes 43: 505-509.
18. Sumida, T. et al. 1994. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int. Immunol. 6: 1445-1449.
19. Skowera, A. et al. 2008. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118: 3390-3402.
20. Willcox, A. et al. 2009. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155: 173-181.
21. Wong, F.S. et al. 1996. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183: 67-76.
22. DiLorenzo, T.P. et al. 1998. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc. Natl. Acad. Sci. USA 95: 12538-12543.
23. Nagata, M. et al. 1994. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J. Immunol. 152: 2042-2050.
24. Dudek, N.L. et al. 2006. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes 55: 2412-2418.
25. Graser, R.T. et al. 2000. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J. Immunol. 164: 3913-3918.
26. Wong, F.S. et al. 2009. Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes 58: 1156-1164.
27. Wang, B. et al. 1996. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 26: 1762-1769.
28. Podack, E.R. et al. 1988. Function of granule perforin and esterases in T cell-mediated reactions. Components required for delivery of molecules to target cells. Ann. N.Y. Acad. Sci. 532: 292-302.
29. Savinov, A.Y. et al. 2003. Contribution of Fas to diabetes development. Proc. Natl. Acad. Sci. USA 100: 628-632.
30. Hamilton-Williams, E.E. et al. 2003. Beta cell MHC class I is a late requirement for diabetes. Proc. Natl. Acad. Sci. USA 100: 6688-6693.
31. Shizuru, J.A. et al. 1988. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 240: 659-662.
32. Haskins, K. et al. 1989. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 86: 8000-8004.
33. Katz, J.D. et al. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74: 1089-1100.
34. Stadinski, B.D. et al. 2010. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11: 225-231.
35. Christianson, S.W., L.D. Shultz & E.H. Leiter. 1993. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42: 44-55.
36. Thivolet, C. et al. 1991. CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. J. Immunol. 146: 85-88.
37. Yagi, H. et al. 1992. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur. J. Immunol. 22: 2387-2393.
38. Varanasi, V. et al. 2012. Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic β-cells. Diabetes 61: 2862-2870.
39. Thomas, H.E. et al. 2009. Beta cell apoptosis in diabetes. Apoptosis 14: 1389-1404.
40. Campbell, I.L. et al. 1991. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87: 739-742.
41. Nicoletti, F. et al. 1996. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology 137: 5567-5575.
42. Sarvetnick, N. et al. 1990. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 346: 844-847.
43. Hultgren, B. et al. 1996. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45: 812-817.
44. Kanagawa, O. et al. 2000. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J. Immunol. 164: 3919-3923.
45. Serreze, D.V. et al. 2000. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 49: 2007-2011.
46. Campbell, I.L. et al. 1989. Intercellular adhesion molecule 1 is induced on isolated endocrine islet cells by cytokines but not by reovirus infection. Proc. Natl. Acad. Sci. USA 86: 4282-4286.
47. Yagi, N. et al. 1995. Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. Diabetes 44: 744-752.
48. Zhang, F. et al. 2002. Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis 161: 381-386.
49. Campbell, I.L. et al. 1988. Regulation of MHC protein expression in pancreatic beta-cells by interferon-gamma and tumor necrosis factor-alpha. Mol. Endocrinol. 2: 101-107.
50. David-Watine, B., A. Israel & P. Kourilsky. 1990. The regulation and expression of MHC class I genes. Immunol. Today 11: 286-292.
51. Stephens, L.A. et al. 1999. Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. Endocrinology 140: 3219-3227.
52. Santamaria, P. 2003. Effector lymphocytes in islet cell autoimmunity. Rev. Endocr. Metab. Disord. 4: 271-280.
53. Cantor, J. & K. Haskins. 2007. Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. J. Immunol. 179: 5760-5767.
54. Lam, G.Y., J. Huang & J.H. Brumell. 2010. The many roles of NOX2 NADPH oxidase-derived ROS in immunity. Semin. Immunopathol. 32: 415-430.
55. Dinauer, M.C. & S.H. Orkin. 1992. Chronic granulomatous disease. Annu. Rev. Med. 43: 117-124.
56. Matute, J.D. et al. 2009. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 114: 3309-3315.
57. Afonso, V. et al. 2007. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 74: 324-329.
58. Weissmann, G. 2004. Pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 10: S26-S31.
59. Gilgun-Sherki, Y., E. Melamed & D. Offen. 2004. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251: 261-268.
60. Mirshafiey, A. & M. Mohsenzadegan. 2009. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 31: 13-29.
61. Roessner, A. et al. 2008. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 204: 511-524.
62. Harrison, D. et al. 2003. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 91: 7A-11A.
63. Bonifacio, E. et al. 1995. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38: 816-822.
64. Khan, M.W. et al. 2009. Characterization of hydroxyl radical modified GAD65: a potential autoantigen in type 1 diabetes. Autoimmunity 42: 150-158.
65. Khan, M.W. et al. 2011. Detection of autoantibodies against reactive oxygen species modified glutamic acid decarboxylase-65 in type 1 diabetes associated complications. BMC Immunol. 12: 19.
66. Babior, B.M., R.S. Kipnes & J.T. Curnutte. 1973. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52: 741-744.
67. Lander, H.M. et al. 1996. Redox regulation of cell signalling. Nature 381: 380-381.
68. Curtsinger, J.M., D.C. Lins & M.F. Mescher. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197: 1141-1151.
69. Janeway, C.A., Jr. 2002. A trip through my life with an immunological theme. Annu. Rev. Immunol. 20: 1-28.
70. Janeway, C.A., Jr. & K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76: 275-285.
71. Janeway, C.A., Jr. & R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.
72. Medzhitov, R. & C. Janeway, Jr. 2000. Innate immunity. N. Engl. J. Med. 343: 338-344.
73. Sklavos, M.M., H.M. Tse & J.D. Piganelli. 2008. Redox modulation inhibits CD8 T cell effector function. Free Radic. Biol. Med. 45: 1477-1486.
74. Tse, H.M. et al. 2007. Disruption of innate-mediated proinflammatory cytokine and reactive oxygen species third signal leads to antigen-specific hyporesponsiveness. J. Immunol. 178: 908-917.
75. Kay, T.W. et al. 2000. The beta cell in autoimmune diabetes: many mechanisms and pathways of loss. Trends Endocrinol. Metab. 11: 11-15.
76. Jackson, S.H. et al. 2004. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 5: 818-827.
77. Chan, A.C., D.M. Desai & A. Weiss. 1994. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu. Rev. Immunol. 12: 555-592.
78. Lenschow, D.J., T.L. Walunas & J.A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
79. Mescher, M.F. et al. 2006. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211: 81-92.
80. Curtsinger, J.M. & M.F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22: 333-340.
81. Curtsinger, J.M. et al. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174: 4465-4469.
82. Ben-Sasson, S.Z. et al. 2009. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl. Acad. Sci. USA 106: 7119-7124.
83. Agarwal, P. et al. 2009. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 183: 1695-1704.
84. Seleme, M.C. et al. 2012. Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice. Free Radic. Biol. Med. 52: 2047-2056.
85. Tse, H.M. et al. 2010. NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J. Immunol. 185: 5247-5258.
86. Van Parijs, L. et al. 1997. Role of interleukin 12 and costimulators in T cell anergy in vivo. J. Exp. Med. 186: 1119-1128.
87. Thomas, H.E. et al. 2004. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 53: 113-121.
88. Hultqvist, M. et al. 2007. Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in mice. J. Immunol. 179: 1431-1437.
89. Hultqvist, M. et al. 2004. Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. Proc. Natl. Acad. Sci. USA 101: 12646-12651.
90. Matsuki, T. et al. 2006. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18: 399-407.
91. Kassiotis, G., K. Kranidioti & G. Kollias. 2001. Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness. J. Neuroimmunol. 119: 239-247.
92. Nakae, S. et al. 2001. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J. Immunol. 167: 90-97.
93. Piganelli, J.D. et al. 2002. A Metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51: 347-355.
94. Thayer, T.C. et al. 2011. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes 60: 2144-2151.
95. George-Chandy, A. et al. 2008. Th17 development and autoimmune arthritis in the absence of reactive oxygen species. J. Immunol. 38: 1118-1126.
96. Efimova, O., P. Szankasi & T.W. Kelley. 2011. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS One 6: e16013.
97. Kraaij, M.D. et al. 2010. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 107: 17686-17691.
98. Mathews, C.E. et al. 2005. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J. Immunol. 175: 1248-1256.
99. Chen, J. et al. 2008. Role of increased ROS dissipation in prevention of T1D. Ann. N.Y. Acad. Sci. 1150: 157-166.
100. Mathews, C.E. et al. 2001. Unusual resistance of ALR/Lt mouse beta cells to autoimmune destruction: role for beta cell-expressed resistance determinants. Proc. Natl. Acad. Sci. USA 98: 235-240.
101. Mathews, C.E. et al. 2003. Genetic analysis of resistance to Type-1 Diabetes in ALR/Lt mice, a NOD-related strain with defenses against autoimmune-mediated diabetogenic stress. Immunogenetics 55: 491-496.
102. Mathews, C.E. et al. 2005. mt-Nd2 Allele of the ALR/Lt mouse confers resistance against both chemically induced and autoimmune diabetes. Diabetologia 48: 261-267.
103. Mathews, C.E. et al. 2002. Genetic control of neutrophil superoxide production in diabetes-resistant ALR/Lt mice. Free Radic. Biol. Med. 32: 744-751.
104. Mandrup-Poulsen, T. et al. 1985. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 40: 424-429.
105. Bendtzen, K. et al. 1986. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232: 1545-1547.
106. Mandrup-Poulsen, T. et al. 1986. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63-67.
107. Lacy, P.E. 1994. The intraislet macrophage and type I diabetes. Mount Sinai J. Med. 61: 170-174.
108. Nerup, J. et al. 1988. Mechanisms of pancreatic beta-cell destruction in type I diabetes. Diabetes Care 11(Suppl 1): 16-23.
109. Comens, P.G. et al. 1987. Interleukin 1 is potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 36: 963-970.
110. Hughes, J.H. et al. 1990. Interleukin 1 inhibits insulin secretion from isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation. J. Clin. Invest. 86: 856-863.
111. Spinas, G.A. et al. 1986. Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinologica 113: 551-558.
112. Lacy, P.E. & E.H. Finke. 1991. Activation of intraislet lymphoid cells causes destruction of islet cells. Am. J. Pathol. 138: 1183-1190.
113. Corbett, J.A. et al. 1992. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J. Clin. Invest. 90: 2384-2391.
114. Eizirik, D.L. 1988. Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinologica 119: 321-325.
115. Scarim, A.L., M.R. Heitmeier & J.A. Corbett. 1997. Irreversible inhibition of metabolic function and islet destruction after a 36-hour exposure to interleukin-1beta. Endocrinology 138: 5301-5307.
116. Lightfoot, Y.L., J. Chen & C.E. Mathews. 2011. Role of the mitochondria in immune-mediated apoptotic death of the human pancreatic beta cell line betaLox5. PLoS One 6: e20617.
117. Lightfoot, Y.L., J. Chen & C.E. Mathews. 2012. Immune-mediated β-cell death in type 1 diabetes: lessons from human β-cell lines. Eur. J. Clin. Invest. 42: 1244-1251.
118. Hibbs, J.B., Jr. 1991. Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res. Immunol. 142: 565-569; discussion 596-568.
119. Ignarro, L.J. 1991. Signal transduction mechanisms involving nitric oxide. Biochem. Pharmacol. 41: 485-490.
120. Moncada, S., R.M. Palmer & E.A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43: 109-142.
121. Nathan, C.F. & J.B. Hibbs, Jr. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3: 65-70.
122. Snyder, S.H. & D.S. Bredt. 1991. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12: 125-128.
123. Southern, C., D. Schulster & I.C. Green. 1990. Inhibition of insulin secretion by interleukin-1 beta and tumour necrosis factor-alpha via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett. 276: 42-44.
124. Corbett, J.A. et al. 1991. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin- 1 beta-induced inhibition of insulin secretion. J. Biol. Chem. 266: 21351-21354.
125. Welsh, N. et al. 1991. Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 129: 3167-3173.
126. Pollock, J.S. et al. 1995. Nitric oxide synthase isozymes antibodies. Histochem. J. 27: 738-744.
127. Corbett, J.A. et al. 1992. Nitric oxide and cyclic GMP formation induced by interleukin 1 beta in islets of Langerhans. Evidence for an effector role of nitric oxide in islet dysfunction. Biochem. J. 287(Pt 1): 229-235.
128. Jitrapakdee, S. et al. 2010. Regulation of insulin secretion: role of mitochondrial signalling. Diabetologia 53: 1019-1032.
129. Koster, J.C. et al. 2000. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell 100: 645-654.
130. Corbett, J.A. & M.L. McDaniel. 1995. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J. Exp. Med. 181: 559-568.
131. Cetkovic-Cvrlje, M. & D.L. Eizirik. 1994. TNF-alpha and IFN-gamma potentiate the deleterious effects of IL-1 beta on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine 6: 399-406.
132. Gysemans, C.A. et al. 2001. Dual role of interferon-gamma signalling pathway in sensitivity of pancreatic beta cells to immune destruction. Diabetologia 44: 567-574.
133. Heitmeier, M.R. & J.A. Corbett. 2000. Cytotoxic role of nitric oxide in diabetes. In Nitric Oxide Biology and Pathobiology. Ignarro, L.J., Ed.: 785-810. Academic Press. San Diego, CA.
134. Heitmeier, M.R., A.L. Scarim & J.A. Corbett. 1997. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J. Biol. Chem. 272: 13697-13704.
135. Corbett, J.A. et al. 1993. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. USA 90: 1731-1735.
136. Eizirik, D.L. et al. 1996. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39: 875-890.
137. Arnush, M. et al. 1998. IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 102: 516-526.
138. Arnush, M. et al. 1998. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J. Immunol. 160: 2684-2691.
139. Corbett, J.A. et al. 1993. A 1-hour pulse with IL-1 beta induces formation of nitric oxide and inhibits insulin secretion by rat islets of Langerhans: evidence for a tyrosine kinase signaling mechanism. FASEB J. 7: 369-374.
140. Corbett, J.A. & M.L. McDaniel. 1994. Reversibility of interleukin-1 beta-induced islet destruction and dysfunction by the inhibition of nitric oxide synthase. Biochem. J. 299: 719-724.
141. Hughes, K.J. et al. 2009. Repair of nitric oxide-damaged DNA in beta-cells requires JNK-dependent GADD45alpha expression. J. Biol. Chem. 284: 27402-27408.
142. Rosales, A.L. et al. 2004. Repair of cytokine-induced DNA damage in cultured rat islets of Langerhans. Free Radic. Res. 38: 665-674.
143. Hughes, K.J. et al. 2009. Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokine-treated beta-cells that is associated with irreversible DNA damage. Am. J. Physiol. Endocrinol. Metabol. 297: E1187-E1196.
144. Delaney, C.A. et al. 1997. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 138: 2610-2614.
145. Eizirik, D.L. & D. Pavlovic. 1997. Is there a role for nitric oxide in beta-cell dysfunction and damage in IDDM Diabetes Metab. Rev. 13: 293-307.
146. Eizirik, D.L. et al. 1994. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc. Natl. Acad. Sci. USA 91: 9253-9256.
147. Eizirik, D.L. et al. 1994. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest. 93: 1968-1974.
148. Welsh, N. et al. 1995. Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Mol. Med. 1: 806-820.
149. Burkart, V. et al. 2000. Natural resistance of human beta cells toward nitric oxide is mediated by heat shock protein 70. J. Biol. Chem. 275: 19521-19528.
150. Scarim, A.L., M.R. Heitmeier & J.A. Corbett. 1998. Heat shock inhibits cytokine-induced nitric oxide synthase expression by rat and human islets. Endocrinology 139: 5050-5057.
151. Weber, S.M., A.L. Scarim & J.A. Corbett. 2003. Inhibition of IFN-gamma -induced STAT1 activation by 15- deoxy-Delta 12, 14-prostaglandin J2. Am. J. Physiol. Endocrinol. Metabol. 284: E883-E891.
152. Weber, S.M. et al. 2004. PPARgamma ligands induce ER stress in pancreatic beta-cells: ER stress activation results in attenuation of cytokine signaling. Am. J. Physiol. Endocrinol. Metabol. 287: E1171-E1177.
153. Steer, S.A. et al. 2006. Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med. 3: e17.
154. Cnop, M. et al. 2005. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2): S97-S107.
155. Eizirik, D.L. & T. Mandrup-Poulsen. 2001. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. [erratum appears in Diabetologia 2002 Jun;45(6):936.] Diabetologia 44: 2115-2133.
156. Gurzov, E.N. & D.L. Eizirik. 2011. Bcl-2 proteins in diabetes: mitochondrial pathways of beta-cell death and dysfunction. Trends Cell Biol. 21: 424-431.
157. Mandrup-Poulsen, T. 2001. beta-cell apoptosis: stimuli and signaling. [Review][63 refs]. Diabetes 50: S58-S63.
158. McKenzie, M.D. et al. 2010. Glucose induces pancreatic islet cell apoptosis that requires the BH3-only proteins Bim and Puma and multi-BH domain protein Bax. Diabetes 59: 644-652.
159. Thomas, H.E. & T.W. Kay. 2011. Intracellular pathways of pancreatic beta-cell apoptosis in type 1 diabetes. Diabetes Metab. Res. Rev. 27: 790-796.
160. Cunha, D.A. et al. 2012. Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis. Diabetes 61: 2763-2775.
161. Lee, H. et al. 2011. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by beta-lapachone treatment. PLoS One 6: e21533.
162. Wang, Q. et al. 2009. IL-1beta caused pancreatic beta-cells apoptosis is mediated in part by endoplasmic reticulum stress via the induction of endoplasmic reticulum Ca2+ release through the c-Jun N-terminal kinase pathway. Mol. Cell Biochem. 324: 183-190.
163. Akerfeldt, M.C. et al. 2008. Cytokine-induced beta-cell death is independent of endoplasmic reticulum stress signaling. Diabetes 57: 3034-3044.
164. Chambers, K.T. et al. 2008. The role of nitric oxide and the unfolded protein response in cytokine-induced beta-cell death. Diabetes 57: 124-132.
165. Collier, J.J. et al. 2006. Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines. Diabetes 55: 1398-1406.
166. Cunningham, J.M. & I.C. Green. 1994. Cytokines, nitric oxide and insulin secreting cells. Growth Regulation 4: 173-180.
167. Collier, J.J. et al. 2011. Pancreatic beta-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One 6: e22485.
168. Scaffidi, P., T. Misteli & M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
169. Zong, W.X. et al. 2004. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18: 1272-1282.
170. Adeghate, E. & S.H. Parvez. 2000. Nitric oxide and neuronal and pancreatic beta cell death. Toxicology 153: 143-156.
171. Hohmeier, H.E. et al. 2003. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int. J. Obesity Relat. Metabol. Disorders. 27(Suppl 3): S12-S16.
172. Rabinovitch, A. 1998. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14: 129-151.
173. Szabadkai, G. & M.R. Duchen. 2009. Mitochondria mediated cell death in diabetes. Apoptosis 14: 1405-1423.
174. Liu, D. et al. 2000. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 49: 1116-1122.
175. Takamura, T. et al. 1998. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J. Biol. Chem. 273: 2493-2496.
176. Meares, G. et al. 2009. AMP-activated protein kinase attenuates nitric oxide-induced beta-cell death. J. Biol. Chem. 285: 3191-3200.
177. Zong, W.X. & C.B. Thompson. 2006. Necrotic death as a cell fate. Genes. Dev. 20: 1-15.
178. Hughes, K. et al. 2009. Repair of nitric oxide-damaged DNA in beta-cells requires JNK-dependent GADD45alpha expression. J. Biol. Chem. 284: 27402-27408.
179. Kim, Y.M., R.V. Talanian & T.R. Billiar. 1997. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem. 272: 31138-31148.
180. Rossig, L. et al. 1999. Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J. Biol. Chem. 274: 6823-6826.
181. Abdelli, S. et al. 2007. The c-Jun N-terminal kinase JNK participates in cytokine- and isolation stress-induced rat pancreatic islet apoptosis. Diabetologia 50: 1660-1669.
182. Gurzov, E.N. et al. 2009. Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differentiation 16: 1539-1550.
183. Larsen, L. et al. 2005. Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia 48: 2582-2590.
184. Scarim, A.L. et al. 2003. Role for c-Jun N-terminal kinase in beta-cell recovery from nitric oxide-mediated damage. Endocrinology 144: 3415-3422.
185. Smith, M.L. & Y.R. Seo. 2002. p53 regulation of DNA excision repair pathways. Mutagenesis 17: 149-156.
186. Tran, H. et al. 2002. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296: 530-534.
187. Hughes, K.J. et al. 2011. FoxO1 and SIRT1 regulate beta-cell responses to nitric oxide. J. Biol. Chem. 286: 8338-8348.
188. Qiang, L., A.S. Banks & D. Accili. 2010. Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J. Biol. Chem. 285: 27396-27401.
189. Giannakou, M.E. & L. Partridge. 2004. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol. 14: 408-412.
190. Motta, M.C. et al. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
191. Corbett, J.A. et al. 1992. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556.
192. Johannesen, J. et al. 2001. Strain-dependent difference in inducible nitric oxide synthesis (iNOS) expression in rat pancreatic islets correlates with interferon regulating factor 1 (IRF-1) and heat shock protein 70 (HSP70) expression. Eur. Cytokine Network 12: 501-509.
193. Eizirik, D.L., A.K. Cardozo & M. Cnop. 2008. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29: 42-61.
194. Andreone, T. et al. 2012. Cytokine-mediated beta-cell damage in PARP-1-deficient islets. Am. J. Physiol. Endocrinol. Metabol. 303: E172-E179.
195. Sareila, O. et al. 2011. NOX2 complex-derived ROS as immune regulators. Antioxid Redox Signal. 15: 2197-2208.